Spectrum Pharmaceuticals' acquisition continued ...
Zevalin is an FDA-approved drug for patients with relapsed or refractory, low-grade or follicular B-cell Non-Hodgkin's Lymphoma. Zevalin is currently under review by the FDA for use as a first-line consolidation therapy, which aims to rapidly improve the quality of response achieved from initial treatments that reduce the number of cancer cells in the body.
If approved, Zevalin will be the first treatment available to patients as a first-line consolidation therapy to treat Non-Hodgkin's Lymphoma. The drug's current patient population would increase by 18,000, and it could be used in several different lines of treatment. A decision is expected in July.
Spectrum Pharmaceuticals is a biopharmaceutical company that acquires, develops and commercializes drug products with a focus on oncology and urology.